breast cancer tissues; adjacent normal breast tissues
MDA-MB-231; MDA-MB-468; MCF7; MCF-10A; MCF-7; SKBR3; 4175; SCP2; HEK293T
cell line-derived xenograft
proliferation (promotes); cell cycle (promotes); EMT (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ceRNA regulation (promotes); apoptosis (inhibits)
Microarray; Bioinformatics Analysis; RT-qPCR; RNase R Treatment; divergent primers PCR; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Transfection; MTT; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; Colony Formation Assay; EdU Staining; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Clinical Sample Validation; Cohort Study; Survival Analysis
high circHMCU expression was significantly correlated with a poor prognosis in breast cancer patients; positively correlated with histological grade, lymph node metastasis, T stage and N stage
circHMCU (hsa_circ_0000247), derived from MCU, is up-regulated in breast cancer tissues and aggressive/metastatic breast cancer cell sublines and is mainly cytoplasmic. It promotes proliferation and metastasis (EMT, migration/invasion, lung metastasis) by sponging let-7 family miRNAs, thereby increasing let-7 target genes including MYC, HMGA2 and CCND1; high circHMCU is associated with poor patient prognosis.
0.8824
circHMCU Promotes Proliferation and Metastasis of Breast Cancer by Sponging the let-7 Family.
combined biological and clinical study